Chemotherapy Before Surgery: — Why It Is Given First

There is no evidence that giving chemotherapy first allows cancer to spread in a way that harms outcome. The concern is understandable — it can feel as though the tumour is being left in place — but chemotherapy is actively treating the cancer during that window, not leaving it untouched. NCCN and ESMO guidance supports this sequence for specific cancer types because the evidence across those types shows outcomes are not worsened by the timing when the treatment plan is followed.

The duration depends on your cancer type and the specific plan your team has set — it is typically a matter of months, with multiple cycles. There is also a recovery interval after the final cycle before surgery takes place. Your oncologist will tell you the planned number of cycles and the overall timeline from the start. Ask them to walk you through the full schedule so you can plan work, family, and travel around it.

No. Neoadjuvant chemotherapy is an established part of treatment planning for certain cancers — including some breast cancers, some stomach and oesophageal cancers, and some rectal cancers — but it is not used universally. If your team has recommended it, there is a reason specific to your cancer type and stage. Ask them which guideline body endorses this sequence for your diagnosis and why it applies to your situation specifically.

Surgeons still operate on the area where the tumour was. Imaging can underestimate response, and complete disappearance on a scan does not always confirm that every cell is gone. The surgical plan is guided by your team's full assessment, not the scan alone. In certain cancer types, active research is examining whether surgery can be reduced after a complete response, but this is not standard practice outside of specific clinical trial settings and would be discussed explicitly with you if it applied.

You can always raise it with your oncologist, and it is a reasonable question. Your team will explain why they have recommended this order for your specific situation. In some cases the sequence is flexible and your preference is a factor; in others, the clinical evidence strongly supports one order and your oncologist will explain why. You are also entitled to seek a second opinion — a good oncologist will not object to that request.

A good response — including a complete pathological response — is a meaningful and positive piece of information. It tells your team that the cancer is sensitive to the treatment used, and it guides decisions about what follows surgery. However, outlook depends on many factors beyond treatment response: the cancer type, stage, and other tumour characteristics all play a role. Your oncologist is the right person to interpret what the response means in your specific situation. Survival figures vary too much by cancer type to apply to individuals, which is why we have not included them here.